# Zevalin Post-marketing Surveillance in Japan

> **NCT01448928** · — · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 400 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma (NHL)

## Interventions

- **DRUG:** [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

## Key facts

- **NCT ID:** NCT01448928
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2021-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448928, "Zevalin Post-marketing Surveillance in Japan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01448928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*